RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望...市場調査レポートについてご紹介

【英文タイトル】RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global RNAi Therapies Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to RNAi Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of RNA: From DNA to Proteins, and Beyond
2.2.1 The Functions of RNA
2.2.2 The Discovery of RNA Interference
2.3 RNAi Timeline: From Discovery to Human Trials
2.4 RNAi: Repurposing a Natural Cellular Gene-Silencing Process
2.4.1 siRNA: Application in Genetic Diseases
2.4.2 miRNA: Natural Gene Expression Regulators
2.5 Development of RNAi Therapies
2.5.1 The Delivery Approach: Exogenous Introduction of siRNA
2.5.2 ddRNAi: Stable Expression of RNAi Inducers
2.5.2.1 shRNA: Employing Viral Vectors
2.6 Ribopharma AG: The First Company to Specialise in RNAi Therapeutics
2.7 Phases of Clinical Trials
2.8 Scope of This Report
2.8.1 Products Excluded from This Report
2.9 Currency Exchange Rates in This Report

3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Areas Driving the RNAi Therapeutics Market to 2025
3.2 Infectious Diseases and Cancer Account for Most Pipeline Therapies in 2015
3.3 Infectious Diseases – Protecting and Saving Lives through Medical Progress
3.3.1 Viral Hepatitis
3.3.1.1 Hepatitis B and C
3.3.1.2 Prospects for RNAi in Hepatitis B and C
3.3.2 Prospects for RNAi in HIV Infection
3.4 Cancer: Great Scope for New Therapies
3.5 Ophthalmic Diseases – Limited Opportunity for Developers?
3.5.1 RNAi for AMD: No Clinical Candidates in 2015
3.5.2 RNAi for Glaucoma: Limited Role in Treatment?
3.6 Lung Diseases and Respiratory Disorders – Life-Improving Treatments
3.6.1 Respiratory Syncytial Virus Infection
3.7 Kidney Disease – Investigations to Treat the Urinary System
3.7.1 Delayed Graft Function (DGF)

4. RNAi Therapies: World Market 2015-2025
4.1 The World RNAi Therapies Market in 2014
4.2 RNAi Therapies Market Segmentation, 2014
4.3 World RNAi Therapies Market: Sales Forecast 2015-2025
4.4 World RNAi Therapies Market: Drivers and Restraints 2015-2025

5. Leading Regional Markets 2015-2025
5.1 Scope and Limitations
5.2 World RNAi Therapies Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change to 2025?
5.4 US RNAi Therapies Market 2015-2025
5.4.1 FDA Approval of Kynamro Improves RNAi Prospects
5.5 EU5 RNAi Therapies Market 2015-2025
5.5.1 RNAi Prospects in Leading EU Markets
5.6 Asia-Pacific RNAi Therapies Market 2015-2025
5.6.1 Prospects for RNAi Therapies in Japan
5.6.2 China Steps Up Efforts in RNAi Drug Development
5.6.3 India: Company Collaborations to Stimulate Interest in RNAi
5.7 Latin American RNAi Therapies Market 2015-2025
5.8 The RNAi Therapies Market in the Rest of the World 2015-2025

6. RNAi Therapies: Leading Companies 2015-2025
6.1 Alnylam Pharmaceuticals
6.1.1 RNAi Therapeutic Pipeline: Strong Portfolio
6.1.1.1 Genetic Medicine STAr
6.1.1.2 Cardio-metabolic Disease STAr
6.1.1.3 Hepatic Infectious Disease STAr
6.1.1.4 Other Pipeline Products: Development on Hold
6.1.1.5 Other Pipeline Products: ALN-RSV01 for RSV Infection
6.1.1.6 Other Pipeline Products: ALN-VSP02 for Liver Cancers
6.1.2 Sales and Recent Performance
6.1.3 Recent Developments
6.1.3.1 Alnylam Files Trade Secret Misappropriation Suit Against Dicerna
6.1.3.2 Alnylam Enters Strategic Alliance with Genzyme (Sanofi)
6.1.3.3 Other Alliances with Leading Companies
6.1.3.4 Acquisition of Sirna Therapeutics
6.1.3.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.2 Arrowhead Research
6.2.1 RNAi Therapeutic Pipeline: Targeting Hepatitis B and Alpha-1 Antitrypsin Deficiency
6.2.2 Sales and Recent Performance
6.2.3 Recent Developments
6.2.3.1 Roche Acquisition Strengthens Company’s Market Position
6.2.3.2 Arrowhead Acquires Novartis’ RNAi Assets
6.3 Benitec Biopharma
6.3.1 RNAi Therapeutic Pipeline
6.3.2 Sales and Recent Performance
6.3.3 Recent Developments
6.3.3.1 ddRNAi Patent Maintained by Australia’s CSIRO
6.3.3.2 Agreement with Omnia Biologics
6.4 Gradalis Incorporated
6.4.1 RNAi Therapeutic Pipeline: Advancing Gradalis for Cancer
6.5 Quark Pharmaceuticals
6.5.1 RNAi Therapeutic Pipeline: A Broad siRNA Portfolio in Clinical Development
6.5.1.1 Preclinical Pipeline: Collaboration with Nitto Denko
6.5.2 Recent Developments
6.5.2.1 Quark Partners with Big Pharma to Develop RNAi Therapies
6.5.2.2 RiboQuark: Joint Venture with Suzhou Ribo Life Science
6.6 Roche Innovation Center Copenhagen
6.6.1 RNAi Therapeutic Pipeline: Potential in Locked Nucleic Acid Platform?
6.6.1.1 Former Santaris Pipeline Candidates
6.6.2 Recent Developments
6.6.2.1 Targeting Rare Genetic Diseases through Alliance with Shire
6.6.2.2 Roche and Isis Pharmaceuticals to Settle Patent Lawsuit?
6.7 RXi Pharmaceuticals
6.7.1 RNAi Therapeutic Pipeline: Lead Candidate RXI-109 Prevents Scar Formation
6.7.2 Sales and Recent Performance
6.7.3 Recent Developments
6.7.3.1 Early Distribution Agreement with Ethicor
6.7.3.2 Acquisition of RNAi Assets from OPKO Health
6.8 Silence Therapeutics
6.8.1 RNAi Therapeutic Pipeline: Lead Candidate Atu027 Completed Phase 2
6.8.1.1 Multiple Delivery Technologies Offers Promise
6.8.2 Sales and Recent Performance
6.8.3 Recent Developments
6.8.3.1 Partnerships for Silence Therapeutics’ RNAi Platform
6.8.3.2 Silence Therapeutics Wins European Patent Office Appeal Covering RNAi Trigger Modification
6.9 Silenseed
6.9.1 RNAi Therapeutic Pipeline
6.9.2 Recent Developments
6.9.2.1 Silenseed IPO Filed in 2014
6.10 Sylentis
6.10.1 RNAi Therapeutic Pipeline: First Spanish Company to Conduct Clinical Trials of an RNAi Drug
6.10.2 Recent Developments
6.10.2.1 Zeltia Subsidiary PharmaMar May Merge with Its Parent Company
6.11 Tekmira Pharmaceuticals
6.11.1 RNAi Therapeutic Pipeline: Focusing on Cancer and Ebola
6.11.2 Sales and Recent Performance
6.11.3 Recent Developments
6.11.3.1 Out-Licensing of LNP Technology Adding Extra Revenue
6.11.3.2 Tekmira Merges with OnCore
6.12 Other Companies of Interest

7. RNAi Therapies: Development Pipeline 2015-2025
7.1 The RNAi Therapies Pipeline
7.2 RNAi Therapies: Phase 3 Pipeline
7.2.1 ALN-TTR02 (patisiran, Alnylam)
7.2.1.1 ALN-TTR02: Sales Forecast 2015-2025
7.2.2 ALN-TTRsc (revusiran, Alnylam)
7.2.2.1 ALN-TTRsc: Sales Forecast 2015-2025
7.2.3 Vigil (Cancer Immunotherapy, Gradalis Incorporated)
7.2.3.1 Vigil: Sales Forecast 2015-2025
7.3 RNAi Therapies: Phase 2 Pipeline
7.3.1 ALN-RSV01 (targeting RSV nucleocapsid, Alnylam)
7.3.2 ARC-520 (targeting conserved regions of HBV, Arrowhead)
7.3.2.1 ARC-520 Clinical Trial Results and Analysis
7.3.2.2 ARC-520: Sales Forecast 2015-2025
7.3.3 Atu027 (targeting PKN3, Silence Therapeutics)
7.3.3.1 Atu027: Sales Forecast 2015-2025
7.3.4 PF-655 (RTP801I-14) (targeting RTP801, Quark)
7.3.4.1 PF-655: Sales Forecast 2015-2025
7.3.5 QPI-1002 (I5NP) (targeting p53, Quark)
7.3.5.1 QPI-1002: Sales Forecast 2015-2025
7.3.6 RXI-109 (targeting CTGF, RXi Pharmaceuticals)
7.3.6.1 RXI-109: Sales Forecast 2015-2025
7.3.7 siG12D-LODER (targeting KRAS, Silenseed)
7.3.7.1 siG12D-LODER: Sales Forecast 2015-2025
7.3.8 SPC3649 (miravirsen) (targeting miR-122, Roche)
7.3.8.1 SPC3649: Sales Forecast 2015-2025
7.3.9 SYL040012 (targeting ADRB2, Sylentis Pharmaceuticals)
7.3.9.1 SYL040012: Sales Forecast 2015-2025
7.3.10 SYL1001 (targeting TRPV1, Sylentis Pharmaceuticals)
7.3.11 TKM-PLK1 Products (targeting PLK1, Tekmira)
7.3.12 TT-034 (targeting Hepatitis C Virus, Benitec Biopharma)
7.4 RNAi Therapies: Phase 1 Pipeline
7.5 RNAi Therapies: Preclinical Pipeline

8. Qualitative Analysis of the RNAi Therapies Market 2015-2025
8.1 SWOT Analysis of the RNAi Therapies Market
8.2 Strengths
8.2.1 A Highly Specific and Selective Therapy
8.2.2 Lower Therapeutic Dosages
8.2.3 Shorter Lead Identification Times
8.2.4 Manufacturing Synthetic RNAs: Cost-Effective and Easier Than for Other Biologics
8.3 Weaknesses
8.3.1 Challenges of Systemic Delivery of RNAi
8.3.1.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
8.3.1.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
8.3.1.3 Industry’s Approach to Overcome the Introduction Challenges
8.3.2 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
8.4 Opportunities
8.4.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
8.4.2 Combination Therapy with Antisense Technology or Aptamers?
8.4.2.1 Antisense Technology: First-to-Market Advantage
8.4.2.2 Aptamers: Offering Advantages over Antibodies
8.4.3 The Untapped Potential of mRNA
8.5 Threats
8.5.1 Novel Class of Treatment May Have Prolonged Approval Process
8.5.2 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
8.5.3 Advances in Alternative Gene-Silencing Approaches Such As CRISPRs
8.6 STEP Analysis of the RNAi Therapies Market
8.6.1 Social Factors
8.6.2 Technological Factors
8.6.3 Economic Factors
8.6.4 Political Factors

9. Research Interviews
9.1 Interview with Mr Joseph Payne, CEO of Arcturus Therapeutics, San Diego, California
9.1.1 Arcturus Therapeutics’ RNAi Therapies Pipeline
9.1.2The Outlook for TTR-Mediated Disease RNAi Therapies?
9.1.3 Barriers to Market Entry
9.1.4 Opportunities for RNAi Developers
9.1.5 Interest from Big Pharma and Investors
9.1.6 Therapeutic Areas and Targets for RNAi Developers
9.1.7 Other Trends and Developments in RNAi Therapeutics
9.2 Interview with Mr J. Michael French, President and CEO of Marina Biotech, Bothell, Washington
9.2.1 Marina Biotech’s RNAi Pipeline and Platform
9.2.2 Barriers to Market Entry
9.2.3 Opportunities for RNAi Developers
9.2.4 Interest from Big Pharma and Investors
9.2.5 Therapeutic Areas and Targets for RNAi Developers
9.2.6 Other Trends and Developments in RNAi Therapeutics

10. Conclusions
10.1 Market Entry of RNAi Therapies Expected in 2015-2025
10.2 The World RNAi Therapies Market in 2014
10.3 Leading RNAi Therapies Companies
10.4 Leading Regional Markets
10.5 World RNAi Therapies Market Forecast 2015-2025
10.6 RNAi Therapies Late-Stage Pipeline
10.7 The Future of the RNAi Therapies Market: Time for a RNAissance?

11. Glossary


【レポート販売概要】

■ タイトル:RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望
■ 英文:RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches
■ 発行日:2015年6月
■ 調査会社:visiongain
■ 商品コード:VGAIN50611
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。